Marco Mario Gottardis from 9 Harris Rd, Princeton, NJ 08540, age 67, Phone: (609)6881750

Us Patents

Method For The Treatment Of A Condition Remediable By Administration Of A Selective Androgen Receptor Modulator
view source
US Patent:

6960474, Nov 1, 2005
Filed:

Jun 20, 2001
Appl. No.:

09/885827
Inventors:

Mark E. Salvati - Lawrenceville NJ, US
Marco M. Gottardis - Princeton NJ, US
Ricardo M. Attar - Lawrenceville NJ, US
John S. Sack - Lawrenceville NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

G01N033/48
US Classification:

436 64, 514425, 514411, 514387, 514379, 514249, 514169
Abstract:

Selective androgen receptor modulators (SARMs) having antagonist activity in hormone-dependent tumors while exhibiting no activity or agonist activity against other nontumor tissues containing the androgen receptor as well as methods for identifying, designing and using SARMs are provided.

Methods For Identifying Or Screening For Agents That Modulate 17Β-Hsd3
view source
US Patent:

7138246, Nov 21, 2006
Filed:

Feb 28, 2005
Appl. No.:

11/068606
Inventors:

Matthew V. Lorenzi - Philadelphia PA, US
Thomas Spires - Monroe NJ, US
Dan You - Cranbury NJ, US
Roberto Weinmann - Princeton NJ, US
Marco Gottardis - Princeton NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

G01N 33/53
G01N 33/567
US Classification:

435 71, 435 72, 435 721, 436 63, 436 86, 436 89, 436501, 436518, 530300, 530350, 5303879
Abstract:

Methods for determining whether a test agent inhibits a 17β-HSD3, the methods comprising: obtaining a recombinant host cell that expresses the 17β-HSD3; obtaining a reaction mixture comprising the 17β-HSD3, androstenedione, and the test agent; measuring the amount of testosterone in the reaction mixture by a scintillation proximity assay (SPA) using SPA beads conjugated with a testosterone-specific antibody, wherein when the amount of testosterone is lower in the presence of a test agent than in the absence of the test agent, the test agent is identified as an inhibitor of the 17β-HSD3.

Polynucleotides Encoding Human Histone Deacetylase Hdac9C
view source
US Patent:

7199227, Apr 3, 2007
Filed:

Jun 14, 2002
Appl. No.:

10/172094
Inventors:

Donald G. Jackson - Lawrenceville NJ, US
Matthew V. Lorenzi - Philadelphia PA, US
Ricardo M. Attar - Lawrenceville NJ, US
Marco Gottardis - Princeton NJ, US
Liana M. Lee - San Francisco CA, US
John N. Feder - Belle Mead NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

C07H 21/04
US Classification:

536 231, 536 232, 4353201, 530350
Abstract:

The present invention relates to newly discovered human histone deacetylases (HDACs), also referred to as histone deacetylase-like polypeptides. The polynucleotide sequences and encoded polypeptides of the novel HDACs are encompassed by the invention, as well as vectors comprising these polynucleotides and host cells comprising these vectors. The invention also relates to antibodies that bind to the disclosed HDAC polypeptides, and methods employing these antibodies. Also related are methods of screening for modulators, such as inhibitors or antagonists, or agonists. The invention also relates to diagnostic and therapeutic applications which employ the disclosed HDAC polynucleotides, polypeptides, and antibodies, and HDAC modulators. Such applications can be used with diseases and disorders associated with abnormal cell growth or proliferation, cell differentiation, and cell survival, e. g. , neoplastic cell growth, and especially breast and prostate cancers or tumors.

Fused Cyclic Succinimide Compounds And Analogs Thereof, Modulators Of Nuclear Hormone Receptor Function
view source
US Patent:

7655688, Feb 2, 2010
Filed:

Dec 19, 2005
Appl. No.:

11/311731
Inventors:

Mark E. Salvati - Lawrenceville NJ, US
Ricardo M. Attar - Lawrenceville NJ, US
Marco M. Gottardis - Princeton NJ, US
James Aaron Balog - Scotch Plains NJ, US
Dacia A. Pickering - Lawrenceville NJ, US
Rogelio L. Martinez - Monmouth Junction NJ, US
Chongqing Sun - East Windsor NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 31/40
A61K 31/47
A61K 31/34
US Classification:

514411, 514408, 514410, 514311, 514312, 514314, 514470, 514307
Abstract:

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Multivalent Fibronectin Based Scaffold Domain Proteins
view source
US Patent:

8221765, Jul 17, 2012
Filed:

May 22, 2009
Appl. No.:

12/470989
Inventors:

Ray Camphausen - Wayland MA, US
Eric Furfine - Concord MA, US
Irvith M. Carvajal - Brighton MA, US
H. Nicholas Marsh - Charlestown MA, US
Marco Gottardis - Princeton NJ, US
Joan Carboni - Yardley PA, US
Ricardo Attar - Lawrenceville NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 38/17
A61K 47/48
C07K 14/71
C07K 14/435
US Classification:

4241921, 4241923, 514 11, 514 93, 514 192, 530350, 530402
Abstract:

The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Bispecific Egfr/Igfir Binding Molecules
view source
US Patent:

8343501, Jan 1, 2013
Filed:

Nov 24, 2009
Appl. No.:

12/625217
Inventors:

Stuart Emanuel - Doylestown PA, US
Linda Engle - Framingham MA, US
Ray Camphausen - Wayland MA, US
Martin C. Wright - Boston MA, US
Ginger Chao - Cambridge MA, US
Marco Gottardis - Princeton NJ, US
Joan Carboni - Yardley PA, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A61K 38/17
A61K 38/39
A61K 47/48
C07K 14/71
C07K 14/435
US Classification:

4241851, 4241931, 514 93, 514 192, 530350, 530402
Abstract:

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Biomarkers And Methods For Determining Sensitivity To Insulin Growth Factor-1 Receptor Modulators
view source
US Patent:

8492328, Jul 23, 2013
Filed:

May 15, 2008
Appl. No.:

12/600504
Inventors:

Fei Huang - Princeton NJ, US
Xia Han - Pennington NJ, US
Rameh Hafezi - Franklin Park NJ, US
Jiwen Chen - Bridgewater NJ, US
Douglas Michael Robinson - Hanover MA, US
Gayle M. Wittenberg - Princeton NJ, US
Ashok Ramesh Dongre - Newtown PA, US
Joan M. Carboni - Yardley PA, US
Ricardo M. Attar - Lawrenceville NJ, US
Warren Hurlburt - Mount Laurel NJ, US
Marco M. Gottardis - Princeton NJ, US
Assignee:

Bristol-Myers Squibb Company - Princeton NJ
International Classification:

A01N 61/00
G01N 33/53
US Classification:

514 1, 435 71
Abstract:

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Transgenic Non-Human Mammals Expressing A Reporter Nucleic Acid Under The Regulation Of Androgen Response Elements
view source
US Patent:

20040068762, Apr 8, 2004
Filed:

Jul 16, 2003
Appl. No.:

10/620514
Inventors:

Ricardo Attar - Lawrenceville NJ, US
David Bol - Gaithersburg MD, US
Marco Gottardis - Princeton NJ, US
Kasim Mookhtiar - Richboro PA, US
Ronald Rowley - Guilford CT, US
Jacek Ostrowski - Jamison PA, US
International Classification:

A01K067/027
C12N005/06
US Classification:

800/018000, 435/354000
Abstract:

A transgenic non-human mammal whose genome comprises a nucleic acid construct, wherein said construct comprises a reporter nucleic acid encoding a reporter operably linked to a promoter comprising an androgen response element (ARE), and said construct further comprises an androgen receptor nucleic acid encoding an androgen receptor, and wherein expression of said reporter nucleic acid is regulated by expression of said androgen receptor nucleic acid. The transgenic non-human mammals can be used as an in vivo model for the identification and development of selective androgen receptor modulators (SARMs) for the treatment of cancer or other disorders associated with defective androgen receptor function.

Resumes

Vice President Of Oncology Innovation

view source

Location:

Princeton, NJ

Industry:

Pharmaceuticals

Work:

The Janssen Pharmaceutical Companies of Johnson & Johnson
Vice President of Oncology Innovation
The Janssen Pharmaceutical Companies of Johnson & Johnson
Vice President at Janssen, Pharmaceutical Companies of Johnson and Johnson
Bristol-Myers Squibb Jun 1998 - Aug 2012
Executive Director

Education:

University of Wisconsin - Madison
Doctorates, Doctor of Philosophy, Biology, Philosophy

Skills:

Oncology
Pharmaceutical Industry
Research
Strategic Planning
Drug Development
Translational Medicine
Biotechnology
Drug Discovery
Biomarkers
Budgets
Clinical Trials
Public Speaking
Leadership
Negotiation
Clinical Development
Photoshop
Admet
Molecular Biology
Microsoft Office
Microsoft Excel
Microsoft Word
Powerpoint
English
Windows
Outlook